"The investigational monoclonal antibody BIIB033 (Biogen) appears not only to improve optic nerve latency in the affected eye of patients with acute optic neuritis (AON), often one of the first manifestations of multiple sclerosis (MS), but also h"...
DOSAGE AND ADMINISTRATION
One drop of ILEVRO™ (nepafenac ophthalmic suspension), 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery.
Use with Other Topical Ophthalmic Medications
ILEVRO™ (nepafenac ophthalmic suspension), 0.3% may be administered in conjunction with other topical ophthalmic medications such as beta-blockers, carbonic anhydrase inhibitors, alphaagonists, cycloplegics, and mydriatics.
If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.
Dosage Forms And Strengths
Sterile ophthalmic suspension 0.3%
1.7 mL in a 4 mL bottle
Storage And Handling
ILEVRO™ (nepafenac ophthalmic suspension), 0.3% is supplied in a white, oval, low density polyethylene DROP-TAINER® dispenser with a natural low density polyethylene dispensing plug and gray polypropylene cap presented in an overwrap. Tamper evidence is provided with a shrink band around the closure and neck area of the package.
1.7 mL in 4 mL bottle NDC 0065-1750-07
Store at 2 -25°C (36 - 77°F).
Protect from light.
Alcon Laboratories, Inc. Fort Worth, Texas 76134 USA. Revised: December 2012This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 1/4/2013
Additional Ilevro Information
Report Problems to the Food and Drug Administration
Get breaking medical news.